AU2001244713A1 - Transporters and drug delivery system by using the same - Google Patents
Transporters and drug delivery system by using the sameInfo
- Publication number
- AU2001244713A1 AU2001244713A1 AU2001244713A AU4471301A AU2001244713A1 AU 2001244713 A1 AU2001244713 A1 AU 2001244713A1 AU 2001244713 A AU2001244713 A AU 2001244713A AU 4471301 A AU4471301 A AU 4471301A AU 2001244713 A1 AU2001244713 A1 AU 2001244713A1
- Authority
- AU
- Australia
- Prior art keywords
- transporters
- same
- delivery system
- drug delivery
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000012377 drug delivery Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Anesthesiology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000101113 | 2000-04-03 | ||
| JP2001056912 | 2001-03-01 | ||
| JP2001-56912 | 2001-03-01 | ||
| JP2000-101113 | 2001-03-01 | ||
| PCT/JP2001/002882 WO2001074400A1 (fr) | 2000-04-03 | 2001-04-03 | Transporteurs et systeme de distribution de medicament les utilisant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001244713A1 true AU2001244713A1 (en) | 2001-10-15 |
Family
ID=26589355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001244713A Abandoned AU2001244713A1 (en) | 2000-04-03 | 2001-04-03 | Transporters and drug delivery system by using the same |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7455855B2 (de) |
| EP (1) | EP1279406A4 (de) |
| KR (1) | KR100777195B1 (de) |
| CN (1) | CN100479862C (de) |
| AU (1) | AU2001244713A1 (de) |
| CA (1) | CA2404737C (de) |
| WO (1) | WO2001074400A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001244713A1 (en) | 2000-04-03 | 2001-10-15 | Santen Pharmaceutical Co. Ltd. | Transporters and drug delivery system by using the same |
| US20040254197A1 (en) * | 2001-09-28 | 2004-12-16 | Santen Pharmaceutical Co., Ltd. | Injections for eye tissues containing drug bonded to polyethlene glycol |
| US7279150B2 (en) * | 2002-01-24 | 2007-10-09 | Barnes-Jewish Hospital | Chelating agents with lipophilic carriers |
| JP4480402B2 (ja) | 2002-03-29 | 2010-06-16 | 日油株式会社 | リン脂質誘導体 |
| DE60318469T2 (de) * | 2002-09-30 | 2008-05-21 | Nof Corp. | Phospholipidderivat |
| JP4403303B2 (ja) | 2003-01-06 | 2010-01-27 | 日油株式会社 | リン脂質誘導体及びその製造方法 |
| JP4526479B2 (ja) | 2003-03-20 | 2010-08-18 | 日油株式会社 | リン脂質誘導体 |
| CA2705785A1 (en) * | 2006-11-14 | 2008-05-22 | Saul Yedgar | Use of lipid conjugates in the treatment of diseases or disorders of the eye |
| AU2009246520B2 (en) | 2008-05-12 | 2012-04-19 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US9095404B2 (en) | 2008-05-12 | 2015-08-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| EP2370110B1 (de) * | 2008-12-25 | 2017-08-02 | Canon Kabushiki Kaisha | Markierungszusammensetzung für intraokulares gewebe, markierungsverfahren für intraokulares gewebe und screeningverfahren |
| EP2600900A4 (de) | 2010-08-06 | 2014-11-19 | Univ Illinois | Supramolekulare multiplex-aggregate zur nicht-viralen ausgabe eines genetischen materials |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| EP3340982B1 (de) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Verbindungen zur behandlung von immun- und entzündungserkrankungen |
| EP3939591A1 (de) | 2016-06-27 | 2022-01-19 | Achillion Pharmaceuticals, Inc. | Chinazolin- und indolverbindungen zur behandlung von medizinischen leiden |
| JP2021519337A (ja) | 2018-03-26 | 2021-08-10 | シー４ セラピューティクス， インコーポレイテッド | Ｉｋａｒｏｓの分解のためのセレブロン結合剤 |
| EP3841086A4 (de) | 2018-08-20 | 2022-07-27 | Achillion Pharmaceuticals, Inc. | Pharmazeutische zusammensetzungen zur behandlung von medizinischen störungen im zusammenhang mit komplementfaktor d |
| WO2020081723A1 (en) | 2018-10-16 | 2020-04-23 | Georgia State University Research Foundation, Inc. | Carbon monoxide prodrugs for the treatment of medical disorders |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4804539A (en) * | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| US5411947A (en) * | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| FR2660193B1 (fr) | 1990-04-03 | 1994-11-04 | Philippe Maincent | Produit opthalmique comportant des nanocapsules, son procede de preparation et utilisation des nanocapsules. |
| DE4120760A1 (de) | 1991-06-24 | 1993-03-04 | 3 M Medica Gmbh | Traegersysteme fuer arzneimittel |
| AU4406793A (en) | 1992-06-04 | 1993-12-30 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
| US5540935A (en) * | 1993-12-06 | 1996-07-30 | Nof Corporation | Reactive vesicle and functional substance-fixed vesicle |
| EP0754046A1 (de) | 1994-04-04 | 1997-01-22 | FREEMAN, William R. | Verwendung der phosphonylmethoxyalkyl-nukleoside zur behandlung des erhöhten innenaugendrucks |
| JP3525516B2 (ja) * | 1994-10-27 | 2004-05-10 | 日本油脂株式会社 | 反応性小胞体、小胞体修飾剤および製造方法 |
| CA2230479A1 (en) * | 1995-09-21 | 1997-03-27 | Andaris Limited | Transcytosis vehicles and enhancers for drug delivery |
| US5641750A (en) | 1995-11-29 | 1997-06-24 | Amgen Inc. | Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product |
| US6071532A (en) * | 1996-10-15 | 2000-06-06 | Emory University | Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof |
| EP0963200B9 (de) | 1996-11-05 | 2005-11-30 | The Children's Medical Center Corporation | Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid |
| US6258351B1 (en) * | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
| EP1053012B1 (de) | 1998-02-09 | 2003-07-23 | Enzon Pharmaceuticals, Inc. | Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen |
| BR9909087A (pt) | 1998-03-26 | 2000-12-05 | Schering Corp | Formulações para proteção de conjugados peg-alfa interferon |
| BRPI9912974B8 (pt) | 1998-08-06 | 2021-05-25 | Univ Duke | conjugados de peg-urato oxidase e seu uso |
| WO2000035422A2 (en) * | 1998-12-18 | 2000-06-22 | Hadasit Medical Research Services & Development Ltd. | Method of administering a compound to multi-drug resistant cells |
| KR20010101981A (ko) | 1999-02-08 | 2001-11-15 | 벤슨 로버트 에이치. | 혈관 내피 성장 인자-2 |
| IL146047A0 (en) | 1999-04-23 | 2002-07-25 | Alza Corp | Releasable linkage and compositions containing same |
| US20020064520A1 (en) * | 1999-08-19 | 2002-05-30 | Yanina Rozenberg | Targeted artificial gene delivery |
| AU785017B2 (en) | 2000-01-10 | 2006-08-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of disease |
| WO2001062827A2 (en) * | 2000-02-22 | 2001-08-30 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| AU2001244713A1 (en) | 2000-04-03 | 2001-10-15 | Santen Pharmaceutical Co. Ltd. | Transporters and drug delivery system by using the same |
| US20040254197A1 (en) | 2001-09-28 | 2004-12-16 | Santen Pharmaceutical Co., Ltd. | Injections for eye tissues containing drug bonded to polyethlene glycol |
| DE10161149B4 (de) * | 2001-12-12 | 2007-03-08 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von Heparin-haltigem Ophthalmikum |
-
2001
- 2001-04-03 AU AU2001244713A patent/AU2001244713A1/en not_active Abandoned
- 2001-04-03 KR KR1020027013171A patent/KR100777195B1/ko not_active IP Right Cessation
- 2001-04-03 WO PCT/JP2001/002882 patent/WO2001074400A1/ja active Application Filing
- 2001-04-03 US US10/240,438 patent/US7455855B2/en not_active Expired - Fee Related
- 2001-04-03 EP EP01917801A patent/EP1279406A4/de not_active Withdrawn
- 2001-04-03 CN CNB018074677A patent/CN100479862C/zh not_active Expired - Fee Related
- 2001-04-03 CA CA2404737A patent/CA2404737C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20030144247A1 (en) | 2003-07-31 |
| KR20030009414A (ko) | 2003-01-29 |
| CA2404737C (en) | 2010-06-29 |
| CA2404737A1 (en) | 2001-10-11 |
| WO2001074400A1 (fr) | 2001-10-11 |
| CN100479862C (zh) | 2009-04-22 |
| KR100777195B1 (ko) | 2007-11-19 |
| US7455855B2 (en) | 2008-11-25 |
| EP1279406A4 (de) | 2007-10-24 |
| CN1420790A (zh) | 2003-05-28 |
| EP1279406A1 (de) | 2003-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001288388A1 (en) | Substance delivery system | |
| AU2123200A (en) | Drug delivery device | |
| EP1545662B8 (de) | Verabreichungssystem für arzneien | |
| AU4985600A (en) | Drug delivery device | |
| AU2001264887A1 (en) | Drug delivery device | |
| AU1719800A (en) | Drug delivery systems and methods | |
| AU2001238386A1 (en) | Medication delivery devices | |
| AU2002244142A1 (en) | Integrated medication delivery system | |
| AU7839900A (en) | Reusable medication delivery device | |
| AU2001235009A1 (en) | Drug delivery apparatus | |
| AU2463701A (en) | Drug delivery system exhibiting permeability control | |
| AU2001244713A1 (en) | Transporters and drug delivery system by using the same | |
| AU4947100A (en) | Drug delivery device | |
| AU2002343555A1 (en) | Eutectic-based self-nanoemulsified drug delivery system | |
| AU2001281171A1 (en) | Medication dispensing system | |
| AU4995100A (en) | Selectable agent delivery system | |
| AU2001270963A1 (en) | Transdermal drug delivery system | |
| AU3837999A (en) | Drug delivery device | |
| AU2001260244A1 (en) | Product delivery system | |
| AU6196600A (en) | Medication reminder system | |
| AU2002222138A1 (en) | Drug delivery system | |
| AU2003285550A1 (en) | Drug delivery system | |
| AU2001244854A1 (en) | Local drug delivery | |
| AU2002210580A1 (en) | Drug delivery system | |
| AU2983100A (en) | Drug delivery vehicle |